Journal article
Single-cell analysis reveals key differences between early-stage and late-stage systemic sclerosis skin across autoantibody subgroups
- Abstract:
- OBJECTIVES: The severity of skin involvement in diffuse cutaneous systemic sclerosis (dcSSc) depends on stage of disease and differs between anti-RNA-polymerase III (ARA) and anti-topoisomerase antibody (ATA) subsets. We have investigated cellular differences in well-characterised dcSSc patients compared with healthy controls (HCs). METHODS: We performed single-cell RNA sequencing on 4 mm skin biopsy samples from 12 patients with dcSSc and HCs (n=3) using droplet-based sequencing (10× genomics). Patients were well characterised by stage (>5 or <5 years disease duration) and autoantibody (ATA+ or ARA+). Analysis of whole skin cell subsets and fibroblast subpopulations across stage and ANA subgroup were used to interpret potential cellular differences anchored by these subgroups. RESULTS: Fifteen forearm skin biopsies were analysed. There was a clear separation of SSc samples, by disease, stage and antibody, for all cells and fibroblast subclusters. Further analysis revealed differing cell cluster gene expression profiles between ATA+ and ARA+ patients. Cell-to-cell interaction suggest differing interactions between early and late stages of disease and autoantibody. TGFβ response was mainly seen in fibroblasts and smooth muscle cells in early ATA+dcSSc skin samples, whereas in early ARA+dcSSc patient skin samples, the responding cells were endothelial, reflect broader differences between clinical phenotypes and distinct skin score trajectories across autoantibody subgroups of dcSSc. CONCLUSIONS: We have identified cellular differences between the two main autoantibody subsets in dcSSc (ARA+ and ATA+). These differences reinforce the importance of considering autoantibody and stage of disease in management and trial design in SSc
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 7.5MB, Terms of use)
-
- Publisher copy:
- 10.1136/ard-2023-224184
- Publication website:
- https://discovery.ucl.ac.uk/10175448/1/ard-2023-224184.full.pdf
Authors
+ Medical Research Council
More from this funder
- Funder identifier:
- 10.13039/501100000265
- Grant:
- MR/T001631/1
- Publisher:
- Elsevier
- Journal:
- Annals of the Rheumatic Diseases More from this journal
- Volume:
- 82
- Issue:
- 12
- Pages:
- 1568-1579
- Publication date:
- 2023-08-14
- DOI:
- EISSN:
-
1468-2060
- ISSN:
-
0003-4967
- Language:
-
English
- Keywords:
- Pubs id:
-
1511225
- Local pid:
-
pubs:1511225
- Source identifiers:
-
W4385802294
- Deposit date:
-
2026-05-12
- ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.
Terms of use
- Copyright date:
- 2023
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record